vs
奥尼兰姆制药（ALNY）与ROKU, INC（ROKU）财务数据对比。点击上方公司名可切换其他公司
ROKU, INC的季度营收约是奥尼兰姆制药的1.1倍（$1.2B vs $1.2B），奥尼兰姆制药净利率更高（17.6% vs -2.2%，领先19.8%），奥尼兰姆制药同比增速更快（96.4% vs -18.3%），过去两年奥尼兰姆制药的营收复合增速更高（33.0% vs 13.6%）
奥尼兰姆制药是美国生物制药企业，2002年成立，总部位于马萨诸塞州剑桥市，专注于研发及商业化针对基因明确疾病的RNA干扰（RNAi）疗法，2016年入选福布斯「100家最具创新力成长企业」榜单。
Roku是美国流媒体技术企业，2002年由安东尼·伍德创立，主营数字媒体播放器、电视硬件生产，流媒体内容分发及平台广告运营。截至2024年覆盖用户达1.45亿，是美国流媒体视频分发领域的市场领导者，业务覆盖澳、加、法、德、英及拉美多国。
ALNY vs ROKU — 直观对比
营收规模更大
ROKU
是对方的1.1倍
$1.2B
营收增速更快
ALNY
高出114.7%
-18.3%
净利率更高
ALNY
高出19.8%
-2.2%
两年增速更快
ALNY
近两年复合增速
13.6%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $1.2B |
| 净利润 | $206.0M | $-27.4M |
| 毛利率 | 82.2% | 35.6% |
| 营业利润率 | 23.0% | 59.7% |
| 净利率 | 17.6% | -2.2% |
| 营收同比 | 96.4% | -18.3% |
| 净利润同比 | — | -361.0% |
| 每股收益（稀释后） | $1.51 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALNYROKU
| Q1 26 | $1.2B | $1.2B | ||
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.2B | $1.2B | ||
| Q2 25 | $773.7M | $1.1B | ||
| Q1 25 | $594.2M | $1.0B | ||
| Q4 24 | $593.2M | $1.2B | ||
| Q3 24 | $500.9M | $1.1B | ||
| Q2 24 | $659.8M | $968.2M |
净利润ALNYROKU
| Q1 26 | $206.0M | $-27.4M | ||
| Q4 25 | $186.4M | $80.5M | ||
| Q3 25 | $251.1M | $24.8M | ||
| Q2 25 | $-66.3M | $10.5M | ||
| Q1 25 | $-57.5M | $-27.4M | ||
| Q4 24 | $-83.8M | $-35.5M | ||
| Q3 24 | $-111.6M | $-9.0M | ||
| Q2 24 | $-16.9M | $-34.0M |
毛利率ALNYROKU
| Q1 26 | 82.2% | 35.6% | ||
| Q4 25 | 75.6% | 43.5% | ||
| Q3 25 | 84.2% | 43.4% | ||
| Q2 25 | 81.6% | 44.8% | ||
| Q1 25 | 88.2% | 43.6% | ||
| Q4 24 | 82.7% | 42.7% | ||
| Q3 24 | 83.6% | 45.2% | ||
| Q2 24 | 89.8% | 43.9% |
营业利润率ALNYROKU
| Q1 26 | 23.0% | 59.7% | ||
| Q4 25 | 12.0% | 4.7% | ||
| Q3 25 | 29.5% | 0.8% | ||
| Q2 25 | -2.1% | -2.1% | ||
| Q1 25 | 3.0% | -5.7% | ||
| Q4 24 | -17.7% | -3.3% | ||
| Q3 24 | -15.4% | -3.4% | ||
| Q2 24 | 7.4% | -7.4% |
净利率ALNYROKU
| Q1 26 | 17.6% | -2.2% | ||
| Q4 25 | 17.0% | 5.8% | ||
| Q3 25 | 20.1% | 2.0% | ||
| Q2 25 | -8.6% | 0.9% | ||
| Q1 25 | -9.7% | -2.7% | ||
| Q4 24 | -14.1% | -3.0% | ||
| Q3 24 | -22.3% | -0.9% | ||
| Q2 24 | -2.6% | -3.5% |
每股收益（稀释后）ALNYROKU
| Q1 26 | $1.51 | $0.57 | ||
| Q4 25 | $1.44 | $0.55 | ||
| Q3 25 | $1.84 | $0.16 | ||
| Q2 25 | $-0.51 | $0.07 | ||
| Q1 25 | $-0.44 | $-0.19 | ||
| Q4 24 | $-0.66 | $-0.24 | ||
| Q3 24 | $-0.87 | $-0.06 | ||
| Q2 24 | $-0.13 | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $2.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $2.7B |
| 总资产 | $5.1B | $4.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALNYROKU
| Q1 26 | $1.7B | $2.4B | ||
| Q4 25 | $1.7B | $2.3B | ||
| Q3 25 | $1.5B | $2.3B | ||
| Q2 25 | $1.1B | $2.3B | ||
| Q1 25 | $1.0B | $2.3B | ||
| Q4 24 | $966.4M | $2.2B | ||
| Q3 24 | $1.1B | $2.1B | ||
| Q2 24 | $968.5M | $2.1B |
股东权益ALNYROKU
| Q1 26 | $1.1B | $2.7B | ||
| Q4 25 | $789.2M | $2.7B | ||
| Q3 25 | $233.9M | $2.6B | ||
| Q2 25 | $250.6M | $2.6B | ||
| Q1 25 | $115.4M | $2.5B | ||
| Q4 24 | $67.1M | $2.5B | ||
| Q3 24 | $32.4M | $2.5B | ||
| Q2 24 | $-3.1M | $2.4B |
总资产ALNYROKU
| Q1 26 | $5.1B | $4.4B | ||
| Q4 25 | $5.0B | $4.4B | ||
| Q3 25 | $4.9B | $4.4B | ||
| Q2 25 | $4.6B | $4.3B | ||
| Q1 25 | $4.2B | $4.2B | ||
| Q4 24 | $4.2B | $4.3B | ||
| Q3 24 | $4.2B | $4.3B | ||
| Q2 24 | $4.0B | $4.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $199.1M |
| 自由现金流经营现金流 - 资本支出 | — | $298.4M |
| 自由现金流率自由现金流/营收 | — | 23.9% |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $640.0M |
8季度趋势，按日历期对齐
经营现金流ALNYROKU
| Q1 26 | — | $199.1M | ||
| Q4 25 | $163.6M | $107.7M | ||
| Q3 25 | $325.1M | $127.6M | ||
| Q2 25 | $153.7M | $109.7M | ||
| Q1 25 | $-118.3M | $138.7M | ||
| Q4 24 | $-94.7M | $79.3M | ||
| Q3 24 | $43.7M | $68.7M | ||
| Q2 24 | $124.2M | $23.4M |
自由现金流ALNYROKU
| Q1 26 | — | $298.4M | ||
| Q4 25 | $140.3M | $106.6M | ||
| Q3 25 | $313.0M | $126.5M | ||
| Q2 25 | $139.4M | $108.6M | ||
| Q1 25 | $-127.3M | $136.8M | ||
| Q4 24 | $-103.8M | $76.8M | ||
| Q3 24 | $39.5M | $67.6M | ||
| Q2 24 | $116.1M | $22.5M |
自由现金流率ALNYROKU
| Q1 26 | — | 23.9% | ||
| Q4 25 | 12.8% | 7.6% | ||
| Q3 25 | 25.1% | 10.4% | ||
| Q2 25 | 18.0% | 9.8% | ||
| Q1 25 | -21.4% | 13.4% | ||
| Q4 24 | -17.5% | 6.4% | ||
| Q3 24 | 7.9% | 6.4% | ||
| Q2 24 | 17.6% | 2.3% |
资本支出强度ALNYROKU
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 0.1% | ||
| Q3 25 | 1.0% | 0.1% | ||
| Q2 25 | 1.8% | 0.1% | ||
| Q1 25 | 1.5% | 0.2% | ||
| Q4 24 | 1.5% | 0.2% | ||
| Q3 24 | 0.8% | 0.1% | ||
| Q2 24 | 1.2% | 0.1% |
现金转化率ALNYROKU
| Q1 26 | — | — | ||
| Q4 25 | 0.88× | 1.34× | ||
| Q3 25 | 1.29× | 5.14× | ||
| Q2 25 | — | 10.45× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALNY
| AMVUTTRA | $889.9M | 76% |
| GIVLAARI | $74.4M | 6% |
| OXLUMO | $51.3M | 4% |
| Royalty revenue | $49.0M | 4% |
| Regeneron Pharmaceuticals | $46.3M | 4% |
| Roche | $35.6M | 3% |
| ONPATTRO | $20.5M | 2% |
ROKU
| Advertising | $612.7M | 49% |
| Subscriptions | $518.5M | 42% |
| Devices | $117.6M | 9% |
